Relmada Therapeutics

Relmada Therapeutics is a clinical-stage biotechnology company developing therapies in oncology and central nervous system disorders. Its lead program, NDV-01 for non-muscle invasive bladder cancer (NMIBC), is advancing into the Phase 3 RESCUE registrational program. Its second program, Sepranolone, targets compulsive behaviors through modulation of GABA A receptor activity and is advancing toward a Phase 2 trial in Prader-Willi syndrome. The company states it builds for the real world with a focus on durable efficacy, favorable safety, and ease of administration.

Relmada Therapeutics is a clinical-stage biotechnology company developing therapies in oncology and central nervous system disorders. Its lead program, NDV-01 for non-muscle invasive bladder cancer (NMIBC), is advancing into the Phase 3 RESCUE registrational program. Sepranolone, its second program, targets compulsive behaviors through modulation of GABA A receptor activity and is advancing toward a Phase 2 trial in Prader-Willi syndrome. The company states that its team brings decades of experience across drug development including discovery, clinical development, regulatory strategy, and commercialization, and that team members have held leadership roles at biopharmaceutical companies including Johnson & Johnson, Eli Lilly, Abbott, and Novartis. Sergio Traversa serves as Chief Executive Officer.

Clinical-stage biotechnology company developing therapies in oncology and central nervous system disorders, focused on durable efficacy, favorable safety, and ease of administration.

• NDV-01

  A sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) in development for non-muscle invasive bladder cancer (NMIBC), designed to enable prolonged bladder exposure and controlled local drug release; it arrives ready to use and is instilled in under five minutes in the urologist's office.

• Sepranolone

  A novel clinical candidate targeting compulsive behaviors through modulation of GABA A receptor activity; a synthetic analog of a naturally occurring antagonist of allopregnanolone (ALLO), advancing toward a Phase 2 clinical trial in Prader-Willi syndrome (PWS).

• 2021.12.09

  Reported2021.12.09

  Relmada prices upsized public stock offering[6]Relmada公布扩大规模的股票公开发行定价prnewswire.com

  Relmada Therapeutics announced pricing of an upsized underwritten public offering of 8,823,530 common shares at $17 per share, with gross proceeds expected to be approximately $150 million. The offering was expected to close on December 13, 2021, subject to customary conditions.

• 2020.05.26

  Reported2020.05.26

  Relmada appoints Molly Harper as EVP of Operations[7]Relmada任命Molly Harper为运营执行副总裁prnewswire.com

  Relmada Therapeutics announced Molly Harper's appointment as Executive Vice President of Operations, with oversight of operations across company functions.

Read more

1. 1Relmada Therapeuticsrelmada.com
2. 2NDV-01relmada.com
3. 3Companyrelmada.com
4. 4Sepranolonerelmada.com
5. 5Relmada Therapeutics, Inc. (United States)wikidata.org
6. 6Relmada公布扩大规模的股票公开发行定价prnewswire.com
7. 7Relmada任命Molly Harper为运营执行副总裁prnewswire.com